» Articles » PMID: 19401695

Correlation of RET Somatic Mutations with Clinicopathological Features in Sporadic Medullary Thyroid Carcinomas

Overview
Journal Br J Cancer
Specialty Oncology
Date 2009 Apr 30
PMID 19401695
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Screening of REarranged during Transfection (RET) gene mutations has been carried out in different series of sporadic medullary thyroid carcinomas (MTC). RET-positive tumours seem to be associated to a worse clinical outcome. However, the correlation between the type of RET mutation and the patients' clinicopathological data has not been evaluated yet. We analysed RET exons 5, 8, 10-16 in fifty-one sporadic MTC, and found somatic mutations in thirty-three (64.7%) tumours. Among the RET-positive cases, exon 16 was the most frequently affected (60.6%). Two novel somatic mutations (Cys630Gly, c.1881del18) were identified. MTC patients were divided into three groups: group 1, with mutations in RET exons 15 and 16; group 2, with other RET mutations; group 3, having no RET mutations. Group 1 had higher prevalence (P=0.0051) and number of lymph node metastases (P=0.0017), and presented more often multifocal tumours (P=0.037) and persistent disease at last control (P=0.0242) than group 2. Detectable serum calcitonin levels at last screening (P=0.0119) and stage IV disease (P=0.0145) were more frequent in group 1, than in the other groups. Our results suggest that, among the sporadic MTC, cases with RET mutations in exons 15 and 16 are associated with the worst prognosis. Cases with other RET mutations have the most indolent course, and those with no RET mutations have an intermediate risk.

Citing Articles

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Chen Y, Dai S, Cheng C, Chen L J Hematol Oncol. 2024; 17(1):130.

PMID: 39709431 PMC: 11663365. DOI: 10.1186/s13045-024-01647-1.


First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.

Li W, Wang Y, Xiong A, Gao G, Song Z, Zhang Y Signal Transduct Target Ther. 2024; 9(1):300.

PMID: 39489747 PMC: 11532403. DOI: 10.1038/s41392-024-02006-9.


Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.

Huai J, Wang F, Zhang W, Lou Y, Wang G, Huang L Front Endocrinol (Lausanne). 2024; 15:1484815.

PMID: 39439561 PMC: 11493660. DOI: 10.3389/fendo.2024.1484815.


Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.

Zhang Y, Zheng W, Zhou S, Gu J, Yu Q, Zhu Y Cell Commun Signal. 2024; 22(1):460.

PMID: 39342195 PMC: 11439284. DOI: 10.1186/s12964-024-01837-x.


Not Only but and Chromosomal Instability Are Seen in Young Patients with Sporadic Medullary Thyroid Carcinoma.

Castroneves L, Mangone F, Lerario A, da Cunha Mercante A, Batista R, Barros L J Endocr Soc. 2024; 8(6):bvae059.

PMID: 38655100 PMC: 11036102. DOI: 10.1210/jendso/bvae059.


References
1.
Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G . Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 1998; 137(1):51-7. DOI: 10.1016/s0303-7207(97)00234-7. View

2.
Andre S, Pinto A, Laranjeira C, Quaresma M, Soares J . Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology. 2007; 74(6):323-7. DOI: 10.1159/000110025. View

3.
Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E . Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2007; 93(3):682-7. DOI: 10.1210/jc.2007-1714. View

4.
Mulligan L, Kwok J, Healey C, Elsdon M, Eng C, Gardner E . Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363(6428):458-60. DOI: 10.1038/363458a0. View

5.
Uchino S, Noguchi S, Sato M, Adachi M, Yamashita H, Watanabe S . Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Jpn J Cancer Res. 2000; 90(11):1231-7. PMC: 5926019. DOI: 10.1111/j.1349-7006.1999.tb00701.x. View